WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317763
CAS#: 86408-72-2 (sodium)
Description: Ecabet Sodium is a prescription eye drop for the treatment of dry eye syndrome. It is a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation. Ecabet Sodium is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.
Hodoodo Cat#: H317763
Name: Ecabet Sodium
CAS#: 86408-72-2 (sodium)
Chemical Formula: C20H26Na2O5S
Exact Mass: 0.00
Molecular Weight: 424.460
Elemental Analysis: C, 56.59; H, 6.17; Na, 10.83; O, 18.85; S, 7.55
Related CAS #: 33159-27-2 (free) 86408-72-2 (sodium) 219773-47-4 (sodium hydrate) 219773-47-4 (sodium pentahydrate)
Synonym: Ecabet Sodium; TA-2711; TA 2711; TA-2711; TA-2711E;
IUPAC/Chemical Name: sodium;(4bS,8R,8aR)-8-carboxy-4b,8-dimethyl-2-propan-2-yl-5,6,7,8a,9,10-hexahydrophenanthrene-3-sulfonate
InChi Key: NQQLQPVASUVBKM-MUMAJMNHSA-L
InChi Code: InChI=1S/C20H28O5S.2Na/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25;;/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25);;/q;2*+1/p-2/t17-,19-,20-;;/m1../s1
SMILES Code: CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)S(=O)(=O)[O-].[Na+]
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 424.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Rah YC, Choi J, Yoo MH, Yum G, Park S, Oh KH, Lee SH, Kwon SY, Cho SH, Kim S,
Park HC. Ecabet sodium alleviates neomycin-induced hair cell damage. Free Radic
Biol Med. 2015 Dec;89:1176-83. doi: 10.1016/j.freeradbiomed.2015.11.007. Epub
2015 Nov 10. PubMed PMID: 26561773.
2: Ahn JY, Choi CH, Lee JW, Park SJ, Kim JW, Chang SK, Han SB. The effect of
sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic
gastric ulcer after endoscopic submucosal dissection: a randomized prospective
study. J Dig Dis. 2015 Feb;16(2):75-82. doi: 10.1111/1751-2980.12214. PubMed
PMID: 25420889.
3: Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy
and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori
eradication: a systematic review and meta-analysis. Helicobacter. 2014
Oct;19(5):372-81. doi: 10.1111/hel.12136. Epub 2014 May 14. Review. PubMed PMID:
24826809.
4: Kim JY, Bae HJ, Choi J, Lim JR, Kim SW, Lee SH, Park ES. Efficacy of
gastro-retentive forms of ecabet sodium in the treatment of gastric ulcer in
rats. Arch Pharm Res. 2014 Aug;37(8):1053-62. doi: 10.1007/s12272-013-0278-0.
Epub 2013 Nov 20. PubMed PMID: 24254934.
5: Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y,
Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori
eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin
versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a
randomized, open-label, phase IV trial. Helicobacter. 2012 Dec;17(6):458-65. doi:
10.1111/j.1523-5378.2012.00971.x. Epub 2012 Jul 2. PubMed PMID: 23066868.
6: Okuda M, Yamamoto N, Fukuda N, Maekawa K, Kusaka T, Hashimoto M, Kotake J,
Koizuka H, Fukuda Y. Effect of ecabet sodium treatment on urea breath test and
stool antigen tests in volunteers with Helicobacter pylori infection. J
Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:100-2. doi:
10.1111/j.1440-1746.2012.07080.x. PubMed PMID: 22486880.
7: Furuta T, Kato M, Sugimoto M, Sasaki M, Kamoshida T, Furukawa K, Inaba T,
Tomita T, Shirai T, Ishii N, Nomura H, Konda Y, Asaka M; Japan Gast Study Group.
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as
the rescue regimen for H. pylori infection. Intern Med. 2011;50(5):369-74. Epub
2011 Mar 1. PubMed PMID: 21372444.
8: Yoshioka K, Ueno Y, Tanaka S, Nagai K, Onitake T, Hanaoka R, Chayama K.
Efficacy of ecabet sodium enema on intractable rectal ulcer after piecemeal
endoscopic mucosal resection for rectal tumor. Clin J Gastroenterol. 2010
Dec;3(6):285-8. doi: 10.1007/s12328-010-0174-9. Epub 2010 Sep 17. PubMed PMID:
26190485.
9: Takagi T, Naito Y, Okuda T, Uchiyama K, Adachi S, Mizushima K, Handa O, Kokura
S, Ichikawa H, Yoshikawa T. Ecabet sodium promotes the healing of
trinitrobenzene-sulfonic-acid-induced ulceration by enhanced restitution of
intestinal epithelial cells. J Gastroenterol Hepatol. 2010 Jul;25(7):1259-65.
doi: 10.1111/j.1440-1746.2010.06263.x. PubMed PMID: 20594253.
10: Lawrance IC. Ecabet sodium: a potential new agent in the management of distal
colitis. J Gastroenterol Hepatol. 2010 Jul;25(7):1182-4. doi:
10.1111/j.1440-1746.2010.06339.x. PubMed PMID: 20594242.
11: Koizumi W, Tanabe S, Nakatani K, Ishido K, Nishimura K, Azuma M, Ae T, Sasaki
T, Higuchi K, Katada C, Nakayama N, Saigenji K. Quadruple therapy with ecabet
sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of
Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin
Pharm Ther. 2010 Jun;35(3):303-7. doi: 10.1111/j.1365-2710.2009.01092.x. PubMed
PMID: 20831531.
12: Asakuma Y, Kudo M, Matsui S, Okada M, Kawasaki M, Umehara Y, Ichikawa T,
Kitai S. Comparison of an ecabet sodium and proton pump inhibitor (PPI)
combination therapy with PPI alone in the treatment of endoscopic submucosal
dissection (ESD)--induced ulcers in early gastric cancer: prospective randomized
study. Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1270-3. PubMed PMID:
19950775.
13: Asaoka D, Nagahara A, Oguro M, Izumi Y, Kurosawa A, Osada T, Kawabe M, Hojo
M, Otaka M, Watanabe S. Characteristic pathological findings and effects of
ecabet sodium in rat reflux esophagitis. World J Gastroenterol. 2009 Jul
28;15(28):3480-5. PubMed PMID: 19630101; PubMed Central PMCID: PMC2715972.
14: Yang Kim H, Hahm KB, Choi MG, Rew JS, Seol SY, Chun HJ, Lee OY, Hong WS.
Prospective multi-center trial for the efficacy of ecabet sodium on the relief of
dyspepsia in korean patients with chronic gastritis. J Clin Biochem Nutr. 2007
Nov;41(3):160-8. doi: 10.3164/jcbn.2007022. PubMed PMID: 18299710; PubMed Central
PMCID: PMC2243240.
15: Mitsuyama K, Tomiyasu N, Masuda J, Yamasaki H, Tsuruta O, Sata M. High
affinity of ecabet sodium for inflamed colonic mucosa in ulcerative colitis. Dig
Dis Sci. 2007 Jun;52(6):1442-3. Epub 2007 Apr 3. PubMed PMID: 17404866.
16: Sasaki K, Iizuka M, Konno S, Shindo K, Sato A, Horie Y, Watanabe S. Ecabet
sodium prevents the delay of wound repair in intestinal epithelial cells induced
by hydrogen peroxide. J Gastroenterol. 2005 May;40(5):474-82. PubMed PMID:
15942712.
17: Kusumoto K, Kawahara T, Kuwano Y, Teshima-Kondo S, Morita K, Kishi K, Rokutan
K. Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced
activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells.
Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G300-7. Epub 2004 Sep
30. PubMed PMID: 15458921.
18: Kim JM, Kim JS, Jung HC, Oh YK, Kim N, Song IS. Inhibition of Helicobacter
pylori-induced nuclear factor-kappa B activation and interleukin-8 gene
expression by ecabet sodium in gastric epithelial cells. Helicobacter.
2003;8(5):542-53. PubMed PMID: 14536001.
19: Murata H, Kawano S, Tsuji S, Kamada T, Matsuzawa Y, Katsu K, Inoue K,
Kobayashi K, Mitsufuji S, Bamba T, Kawasaki H, Kajiyama G, Umegaki E, Inoue M,
Saito I. Combination therapy of ecabet sodium and cimetidine compared with
cimetidine alone for gastric ulcer: prospective randomized multicenter study. J
Gastroenterol Hepatol. 2003 Sep;18(9):1029-33. PubMed PMID: 12911658.
20: Ito M, Tanaka S, Yoshihara M, Chayama K, Haruma K. Single administration of
ecabet sodium diminishes the level of delta-13CO2 in urea breath test. J
Gastroenterol. 2002;37(8):674-5. PubMed PMID: 12203087.
